278 related articles for article (PubMed ID: 32428812)
1. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).
Rolfo C; Cardona AF; Cristofanilli M; Paz-Ares L; Diaz Mochon JJ; Duran I; Raez LE; Russo A; Lorente JA; Malapelle U; Gil-Bazo I; Jantus-Lewintre E; Pauwels P; Mok T; Serrano MJ;
Crit Rev Oncol Hematol; 2020 Jul; 151():102978. PubMed ID: 32428812
[TBL] [Abstract][Full Text] [Related]
2. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
Bennett CW; Berchem G; Kim YJ; El-Khoury V
Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
5. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
6. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
Kerachian MA; Poudineh A; Thiery JP
Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
[TBL] [Abstract][Full Text] [Related]
7. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same?
Kahlert C
Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377
[TBL] [Abstract][Full Text] [Related]
8. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
9. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.
Zeng H; He B; Yi C; Peng J
J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556
[TBL] [Abstract][Full Text] [Related]
11. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy.
Zeng C; Stroup EK; Zhang Z; Chiu BC; Zhang W
Cancer Commun (Lond); 2019 Mar; 39(1):12. PubMed ID: 30922396
[TBL] [Abstract][Full Text] [Related]
12. Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges.
Lustberg MB; Stover DG; Chalmers JJ
Cancer J; 2018; 24(2):61-64. PubMed ID: 29601331
[TBL] [Abstract][Full Text] [Related]
13. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
14. [Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Álvarez-Alegret R; Rojo Todo F; Garrido P; Bellosillo B; Rodríguez-Lescure Á; Rodríguez-Peralto JL; Vera R; de Álava E; García-Campelo R; Remon J
Rev Esp Patol; 2020; 53(4):234-245. PubMed ID: 33012494
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
16. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients.
Rolfo C; Malapelle U; Russo A
Cancer Res; 2022 Aug; 82(16):2826-2828. PubMed ID: 35971678
[TBL] [Abstract][Full Text] [Related]
17. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
Ponti G; Manfredini M; Tomasi A
Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Remon J; García-Campelo R; de Álava E; Vera R; Rodríguez-Peralto JL; Rodríguez-Lescure Á; Bellosillo B; Garrido P; Rojo F; Álvarez-Alegret R
Clin Transl Oncol; 2020 Jun; 22(6):823-834. PubMed ID: 31559582
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy for liver diseases.
Mann J; Reeves HL; Feldstein AE
Gut; 2018 Dec; 67(12):2204-2212. PubMed ID: 30177542
[TBL] [Abstract][Full Text] [Related]
20. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Gerratana L; Davis AA; Shah AN; Lin C; Corvaja C; Cristofanilli M
Curr Treat Options Oncol; 2019 Jun; 20(8):68. PubMed ID: 31256282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
